Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia
article
OA: closed
CC0
Abstract
BackgroundDanazol is frequently used in treating patients with acquired aplastic anaemia (AA) in resource-constraint settings. We aimed to evaluate the cardiometabolic side effects of Danazol in patients with AA.MethodsThis prospective study included newly-diagnosed AA patients ≥13 years of age who were eligible for Danazol monotherapy (10 mg/kg/day, capped at 600 mg/day). Lipid profile and two-dimensional echocardiogram were obtained at the baseline and after 6 months of Danazol treatment. Transfusion of blood products and liver function test-based dose adjustments were done as indicated. Pre- and post-treatment parameters were compared using SPSS software version 25.Results36 patients (median age, 28.5 years) were enrolled. HDL cholesterol decreased by 30 % (p ≤0.001), and LDL cholesterol increased by 11 % (p = 0.002) at the end of 6 months. At the end of 6 months, there was a significant increase in the left ventricular (LV) ejection fraction (p = 0.001), LV mass (p ≤0.001), peak A-velocity (p = 0.01), isovolumetric relaxation time (p = 0.032), and a significant decrease in peak E-velocity (p ≤0.00) and Tei index (p = 0.031). Right ventricular E/A ratio also decreased significantly (p < 0.001).ConclusionsDanazol treatment causes profound dyslipidaemia and potential cardiac dysfunction in patients with AA.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
References (39)
- Action of danazol on plasma lipids and lipoprotein metabolism. via openalex
- Danazol and plasma lipoprotein metabolism via openalex
- Danazol increases T regulatory cells in patients with aplastic anemia via openalex
- Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid via openalex
- doi:10.1016/j.jaci.2004.12.1130 via openalex
- doi:10.1016/0002-9149(86)90771-x via openalex
- doi:10.1177/0960327109104821 via openalex
- W2283333399 via openalex
- W2409042624 via openalex
- doi:10.1007/bf00418510 via openalex
- doi:10.1016/0002-9149(86)90392-9 via openalex
- doi:10.1093/ehjci/jex244 via openalex
- doi:10.1136/bjsm.2006.030171 via openalex
- doi:10.1111/j.1559-4564.2006.05210.x via openalex
- doi:10.1016/j.echo.2014.10.003 via openalex
- doi:10.1002/j.1552-4604.1996.tb04167.x via openalex
- doi:10.15420/cfr.2015.1.2.87 via openalex
- doi:10.1016/j.amjcard.2005.10.026 via openalex
- doi:10.1016/j.jjcc.2019.03.002 via openalex
- doi:10.3389/fonc.2023.1135160 via openalex
- doi:10.3390/jcm11237152 via openalex
- doi:10.1155/2020/3106012 via openalex
- doi:10.1186/s44156-024-00051-2 via openalex
- W6695845664 via openalex
- W6714444516 via openalex
- W6715458637 via openalex
- W6779883391 via openalex
- W6852098804 via openalex
- doi:10.1016/s0002-8703(03)00322-3 via openalex
- doi:10.1016/j.ijcard.2007.12.027 via openalex
- doi:10.1007/s00059-006-2856-0 via openalex
- doi:10.1016/j.bcmd.2024.102857 via openalex
- doi:10.1016/0735-1097(92)90478-6 via openalex
- doi:10.1016/j.echo.2018.11.011 via openalex
- doi:10.1016/j.ihj.2014.03.005 via openalex
- doi:10.1016/j.echo.2008.11.023 via openalex
- doi:10.1179/1607845414y.0000000196 via openalex
- doi:10.1016/s0735-1097(97)00344-6 via openalex
- doi:10.1016/j.atherosclerosis.2007.09.025 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:58:58.389534+00:00
- unpaywall
- last seen: 2026-07-30T08:32:49.343555+00:00
License: CC0
· commercial use OK